StockData

Yubo International Biotech Ltd (YBGJ) stock

YBGJOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$0.01+0.00 (0.00%)

Close on Oct 16, 2026Market cap $886.19KP/E –Yield –

Yubo International Biotech Ltd reported revenue of $12.35K for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $886.19K.

Revenue
$12.35K
TTM Q2 2027
Operating income
-$1.12M
TTM Q2 2027
EPS, diluted
$0.00
TTM Q2 2027

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$886.19K
P/E ratio
–
Price to sales
71.74
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$12.35K
Net income
-$1.01M
EPS, diluted
$0.00
Book value per share
-$0.02
Diluted shares
170M

Trading

Previous close
$0.01
Open
$0.01
Day's range
$0.01 – $0.01
Volume
0

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodYBGJS&P 500DifferenceYBGJ per yearS&P 500 per year
1 month-1.9%+1.5%−3.4 pts
3 months-65.1%+1.9%−67.0 pts
Year to date-58.1%+12.8%−70.9 pts
1 year-61.8%+16.8%−78.5 pts
3 years-99.0%+81.5%−180.5 pts-78.7%+22.0%
5 years-98.9%+83.0%−181.9 pts-59.2%+12.8%

Fifteen years at a glance

Fiscal years 2011 to 2026 and trailing twelve months, USD

Revenue

$12.35K

Gross profit

$8.17K

Operating income

-$1.12M

Net income

-$1.01M

EPS, diluted

$0.00

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Yubo International Biotech filed with the SEC as exhibits to Form 8-K or 6-K

About Yubo International Biotech

Electromedical & Electrotherapeutic Apparatus

The company is a biotechnology enterprise that focuses on the research, development, and commercial application of endometrial stem cells. Through its Chinese operating affiliate, it markets various consumer goods under the VIVCELL brand name, including skincare, hair care, respiratory healthcare products, healthy beverages, and personal care items for men and women. In addition to physical goods, the business provides specialized stem cell solutions such as cell testing and health management consulting. Its customer base consists of individual consumers who purchase its personal healthcare items and clients who utilize its diagnostic and wellness advisory services.

Company profile, executives and history

Yubo International Biotech stock: common questions

What is Yubo International Biotech's stock price?

YBGJ closed at $0.01 on Oct 16, 2026, up 0.00% on the day.

What is Yubo International Biotech's market cap?

Yubo International Biotech was worth $886.19K at the close on Oct 16, 2026: the share price times the diluted shares outstanding.

What is YBGJ's P/E ratio?

Yubo International Biotech lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

How much revenue does Yubo International Biotech make?

Yubo International Biotech reported revenue of $12.35K for the twelve months to Jun 30, 2026.

Does Yubo International Biotech pay a dividend?

No. Yubo International Biotech has not paid a cash dividend over the last twelve months.

How has YBGJ stock performed over the past year?

Including dividends, YBGJ returned -61.8% over the past year, against +16.8% for the S&P 500.

Who are Yubo International Biotech's competitors?

Companies most similar to Yubo International Biotech by business, industry and size include CUPR, ITOC, NXL, VRAX, GIPL.

See a number that looks wrong?